Contraindicated (1)bortezomib will raise the amount or effect of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may raise mavacamten systemic exposure, resulting in coronary heart failure because of systolic dysfunction. Geometrically, the square root of two would be the length of the diagonal across https://mylesyenzd.oblogation.com/26549703/cp-866087-fundamentals-explained